IKBKE overexpression is linked to chemotherapy resistance, particularly to cisplatin and paclitaxel in breast and ovarian cancers, as well as resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer (18–21). This evidence concerns the gene EGFR and non-small cell lung carcinoma.